Trial Profile
Efficacy, Safety and Tolerability of Zolpidem in the Treatment of Children Aged 6 to 17 Years With ADHD-Associated Insomnia. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2009
Price :
$35
*
At a glance
- Drugs Zolpidem (Primary)
- Indications Attention-deficit hyperactivity disorder; Insomnia
- Focus Therapeutic Use
- Sponsors Sanofi
- 09 Dec 2008 Actual end date and patient number reported by Clinicaltrials.gov.
- 13 Sep 2006 New trial record.